Evidence map›Paper›PMID 41720862›Full record

ArticleScientific reports2026

Molecular signatures of oocyte viability identified by follicular fluid proteomics.

Stine Gry Kristensen, Cristina Subiran Adrados, Kevin Elsner, Jesus Cadenas, Lea Bejstrup Jensen, Mette Honnens Tanvig, Vinnie Hornshøj Greve, Lotte Berdiin Colmorn, György Marko-Varga, Johan Malm and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Stine Gry Kristensen *Laboratory of Reproductive Biology, Department of Gynaecology, Fertility and Obstetrics, University Hospital of Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark.
Cristina Subiran Adrados *Laboratory of Reproductive Biology, Department of Gynaecology, Fertility and Obstetrics, University Hospital of Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark. cristina.subiran.adrados@regionh.dk.
Kevin ElsnerSection for Clinical Chemistry, Department of Translational Medicine, Skåne University Hospital Malmö, Lund University, 205 02, Malmö, Sweden.
Jesus CadenasLaboratory of Reproductive Biology, Department of Gynaecology, Fertility and Obstetrics, University Hospital of Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark.
Lea Bejstrup JensenLaboratory of Reproductive Biology, Department of Gynaecology, Fertility and Obstetrics, University Hospital of Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark.
Mette Honnens TanvigThe Fertility Clinic, Department of Obstetrics and Gynaecology, Odense University Hospital, Odense, Denmark.
Vinnie Hornshøj GreveDepartment of Obstetrics and Gynaecology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 82, 8200, Aarhus N, Denmark.
Lotte Berdiin ColmornThe Fertility Clinic, Department of Gynaecology, Fertility and Obstetrics, University Hospital of Copenhagen, Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.
György Marko-VargaSection for Clinical Chemistry, Department of Translational Medicine, Skåne University Hospital Malmö, Lund University, 205 02, Malmö, Sweden.
Johan MalmSection for Clinical Chemistry, Department of Translational Medicine, Skåne University Hospital Malmö, Lund University, 205 02, Malmö, Sweden.
Jeovanis GilSection for Clinical Chemistry, Department of Translational Medicine, Skåne University Hospital Malmö, Lund University, 205 02, Malmö, Sweden. jeovanis.gil_valdes@med.lu.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Women are born with thousands of ovarian follicles, yet less than 1% will ovulate a mature oocyte. What distinguishes the 99% of follicles destined for demise from the rare 1% that succeed? Here, we leveraged a unique clinical opportunity, paired follicular fluid samples from small antral follicles containing either a viable or an atretic oocyte within the same patients, to uncover the proteomic determinants governing oocyte fate. Our analysis identified nearly 1,500 proteins. Follicular fluid from healthy follicles was enriched with proteins crucial for energy metabolism, antioxidative defense, structural integrity, and robust intercellular signaling networks, supporting oocyte survival and maturation. In contrast, follicular fluid from atretic oocytes exhibited a distinct inflammatory signature characterized by acute-phase and immune activation proteins, indicative of active degeneration. These novel proteomic insights deepen our understanding of human follicle biology and open new avenues for biomarker development, optimization of assisted reproductive technologies, and targeted therapeutic strategies to preserve and enhance female fertility.

Indexed as

Follicular FluidOocytesProteomeProteomicsAdultBiomarkersCell SurvivalFemaleHumansOvarian FollicleBiomarkersProteomeBiomarkersFollicular atresiaFollicular fluidOocyte viabilityProteomics

Identifiers

PMID41720862
PMCPMC13022172

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.